Virgile Audi

Ramp Network is a fiat <> crypto, non-custodial, full-stack infrastructure. We’re solving real-world problems in a fast-moving industry to make Web3 a reality and to bring about the internet of value. What we deliver to our partners; Wider Blockchain Ecosystem Coverage, Transparent Competitive Pricing and World-Class Compliance. We help businesses implement a solution that removes complexity, increases trust, and reduces friction for customers moving between crypto and fiat.

Matera is a PropTech Saas company that allows co-owners to manage their buildings themselves without the services of a professional property manager. With a third round of funding of 35 million euros, Matera is moving up a gear! Today we have 3,000 client co-ownerships with a target of 5,000 very soon. With more than 400 new applications per week, there is no shortage of people who wish to change their way of managing their building! Founded in 2017, we are now 150 Materani working a lot to achieve our mission: make co-owners happy in their building! It is now the time to address the German market. Why join us? 🏆 A very rewarding job and customers who love us (just have a look at the google reviews about us :) ) 🤗 A team always in a good mood to approach a market where no startup has yet managed to make a name for itself. 💜 You improve the daily life of all your relatives who are mad at their property manager. 👍 Our company’s culture facilitate fulfillment of every employees by adopting solid working methods

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.

Cazoo. Right for You. Search over 230,000 used cars from 6,000 dealers nationwide.

Mubadala Capital was established in 2011, and in 2017, we became one of the first sovereign wealth-affiliated alternative asset managers to manage third-party capital on behalf of institutional investors across the globe. In just over a decade, we have built a new type of investment firm, one designed to evolve alongside the shifting alternative investment landscape and meet the needs of investors of all types, including private wealth. Our ability to navigate complexity and unlock value positions us ahead of market trends, while our commitment to building enduring businesses enables long-term, sustainable returns. Learn more at www.mubadalacapital.ae

Currently working on something new and very exciting

Ramp Network is a fiat <> crypto, non-custodial, full-stack infrastructure. We’re solving real-world problems in a fast-moving industry to make Web3 a reality and to bring about the internet of value. What we deliver to our partners; Wider Blockchain Ecosystem Coverage, Transparent Competitive Pricing and World-Class Compliance. We help businesses implement a solution that removes complexity, increases trust, and reduces friction for customers moving between crypto and fiat.

Matera is a PropTech Saas company that allows co-owners to manage their buildings themselves without the services of a professional property manager. With a third round of funding of 35 million euros, Matera is moving up a gear! Today we have 3,000 client co-ownerships with a target of 5,000 very soon. With more than 400 new applications per week, there is no shortage of people who wish to change their way of managing their building! Founded in 2017, we are now 150 Materani working a lot to achieve our mission: make co-owners happy in their building! It is now the time to address the German market. Why join us? 🏆 A very rewarding job and customers who love us (just have a look at the google reviews about us :) ) 🤗 A team always in a good mood to approach a market where no startup has yet managed to make a name for itself. 💜 You improve the daily life of all your relatives who are mad at their property manager. 👍 Our company’s culture facilitate fulfillment of every employees by adopting solid working methods

Exscientia is a global pharmatech company using patient-first artificial intelligence (AI) to discover better drugs, faster. Our mission is to encode, automate and transform every stage of the drug design and development process, by combining the latest AI techniques with experimental innovation, to enable the design of patient centric drug candidates with an improved probability of success. Our validated platform has delivered the first three AI-designed drugs to enter clinical trials and is the first AI system proven to improve clinical outcomes in oncology. We’ve significantly accelerated pre-clinical drug discovery, with 10x productivity improvement in delivering a drug candidate compared with industry standards. By actively applying AI to precision engineer medicines more rapidly and efficiently, we allow the best ideas of science to rapidly become the best medicines for patients.

Owkin is building the first BASI to unlock breakthroughs in therapies, diagnostics, and rejuvenation, while reshaping how humanity understands and engineers biology. Like other frontier AI companies, we believe the leap from narrow tools to true reasoning systems marks the start of a new era — where intelligence is not just assisting scientists but autonomously advancing discovery. Owkin’s moats are structural and compounding. We are creating the only large-scale reasoning model trained natively on patient-level multimodal data and reinforced through real biological feedback — a closed-loop system that continuously improves itself. Exclusive partnerships with world-class hospitals, unique longitudinal datasets, and automated lab infrastructure create a defensibility flywheel similar to the data moats seen in other generational AI companies. By uniting reasoning models, agentic workflows, and living biological systems, Owkin is building the operating system for biology — a platform no one else can replicate, and the inevitable leader in general-purpose biology intelligence.